PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Higher co-payments increase chance of early discontinuation, inadequate use of breast cancer therapy

2010-12-12
(Press-News.org) SAN ANTONIO — A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early-stage breast cancer.

Dawn L. Hershman, M.D., M.S., associate professor of medicine and epidemiology and co-director of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at Columbia University, presented detailed study results at the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010.

Previous research has identified several factors affecting patient compliance with use of adjuvant aromatase inhibitors, such as young and old age, severity of side effects and belief that the medication is useful.

Hershman and colleagues examined the impact of prescription co-payments on hormone therapy use. Working with the Medco Research Institute, a wholly owned subsidiary of Medco Health Solutions, Inc., anonymous patient information was used to target women older than 50 years who were prescribed aromatase inhibitors for early breast cancer.

"We looked at two different factors: women who discontinued use altogether or had no subsequent refills and those that did not refill their prescription on time or did not take the medication at least 80 percent of the time," said Hershman.

Results showed that of the 8,110 women aged 50 to 65 years, 21.1 percent stopped taking the medication and of those who properly continued with their regimen 10.3 percent did not take the medication as directed over the two-year period. Of the 14,050 women 65 years or older, almost 25 percent stopped taking the medication and of those who continued, 8.9 percent were non-adherent.

Co-payments were categorized as less than $30, between $30 and $89.99, and $90 or more. The 90-day co-payments ranged from $0 to $893.49.

In the 65 and older group, women were more likely to discontinue medication use if they fell in the co-payment categories above $30. However, it was not until the co-payment reached $90 or more that the less than 65 age group was more likely to discontinue use or not take it as prescribed.

Additionally, the study results showed that women whose prescriptions came from a primary care doctor or women who were prescribed many other medications were also more likely to stop taking the medications or not take them as prescribed.

"When we have highly effective medications available, we need to try to set limits on potential barriers to use like co-payments," said Hershman. Based on these findings, "future public policy efforts should be directed towards reducing financial constraints as a means of increasing the complete use of these medications."

### Follow the AACR on Twitter @AACR, and throughout the meeting using the hash tag #SABCS.

Recordings of the teleconferences and video interviews with researchers will posted to the AACR website throughout the meeting: http://www.aacr.org/page23506.aspx.

The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor, and the AACR's scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. The 33rd annual symposium is expected to draw nearly 9,000 participants from more than 90 countries.


ELSE PRESS RELEASES FROM THIS DATE:

Unique needs and outcomes of pregnant women with breast cancer identified

2010-12-12
SAN ANTONIO — Do not delay treatment of breast cancer just because a woman is pregnant, said lead researcher Sibylle Loibl, Dr. med, of the German Breast Group. This suggestion is based on study results detailing the effects of different treatment options on the infant. Loibl presented this data at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010. "At the time we started the study in 2003, there was hardly any information on breast cancer therapy during pregnancy, but we felt there was a medical need for it," she said. Although ...

Novel imaging technique may reduce lymphedema in breast cancer patients

2010-12-12
SAN ANTONIO -- With guidance from a specialized scan, radiation oncologists at Mayo Clinic (http://www.mayoclinic.org/) were able to reduce by 55 percent the number of lymph nodes critical for removing fluid from the arm that received damaging radiation doses. VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Andrea Cheville and other researchers presenting at San Antonio Breast Cancer Symposium, are available on the Mayo Clinic News Blog (http://newsblog.mayoclinic.org/2010/12/06/lymphedema-study/). These materials also ...

Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say

2010-12-12
SAN ANTONIO -- Results for testing breast tumors for HER2 (http://www.mayoclinic.com/health/breast-cancer/AN00495) proteins and genes is most often straightforward when one piece of tumor (a single tumor block) is analyzed. However, tumors can be diverse, and researchers at Mayo Clinic (http://www.mayoclinic.org/) found that HER2 results can vary in up to 10 percent of patients when several tumor blocks are analyzed. This could have significant implications for patient treatment, say the researchers, who are presenting their findings at the 33rd Annual CTRC-AACR San ...

Higher co-payments increase chance of early discontinuation of breast cancer therapy

2010-12-12
A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early stage breast cancer. Dawn L. Hershman, MD, associate professor of medicine and epidemiology and co-director of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at Columbia University, will be presenting detailed study results at The 33rd CTRC-AACR San Antonio Breast Cancer Symposium, a comprehensive scientific meeting ...

Depression drug may relieve pain from breast cancer treatment, U-M study finds

2010-12-12
ANN ARBOR, Mich. — A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center. The women in the study were taking aromatase inhibitors, a type of drug designed to block the production of estrogen, which fuels some breast cancers. About half of women taking these drugs experience aches and pains in their joints and muscles that cannot be adequately relieved by over-the-counter painkillers. Up to 20 ...

Ubiquitous sugar molecule could be key to repairing deep wound without scarring

2010-12-12
Blocking fragments of the sugar molecule hyaluronan that triggers inflammation could be the key to robust healing and less scarring in deep wounds, Canadian researchers reported at the American Society for Cell Biology's 50th Annual Meeting in Philadelphia. In laboratory rats, the small peptide, named 15-1, which blocks fragments of the ubiquitous sugar molecule, hyaluronan, promoted wound healing, minimized scarring and forged stronger new tissue. These effects did not occur in the untreated animals in the study, according to Cornelia Tölg, Ph.D., of the London (Ontario) ...

Pomegranate juice components inhibit cancer cell migration; in vivo testing planned

2010-12-12
Researchers at the University of California, Riverside (UCR), have identified components in pomegranate juice that seem to inhibit the movement of cancer cells and weaken their attraction to a chemical signal that has been shown to promote the metastasis of prostate cancer to the bone, according to a presentation today at the American Society for Cell Biology's 50th Annual Meeting in Philadelphia. The researchers in the UCR laboratory of Manuela Martins-Green, Ph.D., plan additional testing in an in vivo model for prostate cancer to determine dose-dependent effects and ...

Human spermatogonial stem cells become insulin-secreting pancreatic cells in lab

2010-12-12
Insulin-secreting pancreatic islet cells have been generated from human spermatogonial stem cells (SSCs) directly isolated from human testicular tissue, researchers reported today at the American Association of Cell Biology 50th Annual Meeting in Philadelphia. When grafted into diabetic mice that lacked a transplant-rejecting immune system, the bioengineered cells functioned much like somatic β-islet cells, the Georgetown University (GU) Medical Center researchers said. By decreasing the animals' blood glucose levels, the human-derived islet cells demonstrated ...

'Grow your own transplant' may be possible for men with type 1 diabetes

2010-12-12
PHILADELPHIA – Men with type 1 diabetes may be able to grow their own insulin-producing cells from their testicular tissue, say Georgetown University Medical Center (GUMC) researchers who presented their findings today at the American Society of Cell Biology 50th annual meeting in Philadelphia. Their laboratory and animal study is a proof of principle that human spermatogonial stem cells (SSCs) extracted from testicular tissue can morph into insulin-secreting beta islet cells normally found in the pancreas. And the researchers say they accomplished this feat without use ...

Canadian scientists identify a spontaneously chain-reacting molecule

2010-12-12
In the burgeoning field of nano-science there are now many ways of 'writing' molecular-scale messages on a surface, one molecule at a time. The trouble is that writing a molecule at a time takes a very long time. "It is much better if the molecules can be persuaded to gather together and imprint an entire pattern simultaneously, by themselves. One such pattern is an indefinitely long line, which can then provide the basis for the ultimately thin molecular 'wire' required for nano-circuitry," says John Polanyi of the University of Toronto's Department of Chemistry, co- ...

LAST 30 PRESS RELEASES:

SOX2: a key player in prostate cancer progression and treatment resistance

Unlocking the potential of the non-coding genome for precision medicine

Chitinase-3-like protein 1: a novel biomarker for liver disease diagnosis and management

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: August 22, 2025

Charisma Virtual Social Coaching named a finalist for Global Innovation Award

From the atmosphere to the abyss: Iron's role in Earth's climate history

US oil and gas air pollution causes unequal health impacts

Scientists reveal how microbes collaborate to consume potent greenhouse gas

UMass Amherst kinesiologist receives $2 million ‘outstanding researcher’ award from NIH

Wildfire peer review report for land Brandenburg, Germany, is now online

Wired by nature: Precision molecules for tomorrow's electronics

New study finds hidden body fat is linked to faster heart ageing

How a gift card could help speed up Alzheimer’s clinical research

Depression and anxiety symptoms in adults displaced by natural disasters

Cardiovascular health at the intersection of race and gender in Medicare fee for service

World’s first observation of the transverse Thomson effect

Powerful nodes for quantum networks

Mapping fat: How microfluidics and mass spectrometry reveal lipid landscapes in tiny worms

ATOX1 promotes hepatocellular carcinoma carcinogenesis via activation of the c-Myb/PI3K/AKT signaling pathway

Colibactin-producing E. coli linked to higher colorectal cancer risk in FAP patients

Animal protein not linked to higher mortality risk, study finds

Satellite insights into eutrophication trends on the Qinghai–Tibet plateau

Researchers develop an innovative method for large-scale analysis of metabolites in biological samples

Asteroid Bennu is a time capsule of materials bearing witness to its origin and transformation over billions of years

New AI model can help extend life and increase safety of electric vehicle batteries

Wildfires can raise local death rate by 67%, shows study on 2023 Hawaiʻi fires

Yogurt and hot spring bathing show a promising combination for gut health

Study explains how lymphoma rewires human genome

New Durham University study counters idea that Jupiter’s mysterious core was formed by a giant impact

Global study shows racialized, Indigenous communities face higher burden of heart disease made worse by data gaps

[Press-News.org] Higher co-payments increase chance of early discontinuation, inadequate use of breast cancer therapy